bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
bluebird bio 4th Quarter & Full Year 2022 Earnings Call Read more about bluebird bio 4th Quarter & Full Year 2022 Earnings Call
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference Read more about bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
bluebird bio Sells Second Priority Review Voucher for $95 Million Read more about bluebird bio Sells Second Priority Review Voucher for $95 Million
41st Annual J.P. Morgan Healthcare Conference Read more about 41st Annual J.P. Morgan Healthcare Conference
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer Read more about bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer